The JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) trial, which ran from February 2003 to August 2008, showed that compared to placebo, long term use of AstraZeneca’s statin Crestor (rosuvastatin) may lower risk of heart attacks and strokes in people with normal levels of cholesterol.
The participants were 17,802 men over 50 and women over 60 years of age, in over 850 locations worldwide, with no previous cardiovascular disease, and without diabetes, with low to normal levels of LDL (the “bad” cholesterol) and high levels of high sensitivity C-reactive protein (hs-CRP, a blood marker of inflammation, used as a rough indicator of heart disease risk).
What exchange for these questions there weather? You add up to into any search engine… Also you search.
Not important what seeking pattern – google, yahoo or to the core bing...
Beautiful post, great ))
Thank you, I come back